Tag Archive for: appointments

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]

iOnctura bolsters leadership team with new appointments

Steven Sciuto joins as Chief Financial Officer (CFO) bringing a wealth of experience in scaling finance functions as well as in private and public financings Michelle Tsai PharmD, with deep expertise in portfolio strategy and lifecycle planning, joins as Chief Operating Officer (COO) Geneva, Switzerland and Amsterdam, The Netherlands, 2 June 2025 – iOnctura, a […]

Astraveus Strengthens Leadership Team and Board

Jean-Paul Mangeolle joins as Chairman of the Board of Directors David Newble appointed as an Independent Board Member Laurence Riot Lamotte appointed as Chief Financial Officer New hires reflect continuing progress at Astraveus as Company prepares for launch of the Lakhesys Benchtop Cell FactoryTM Paris, France, 15 April 2025 – Astraveus SAS (“Astraveus” or the […]

Ottimo Pharma Strengthens Leadership Team with Senior Appointments

Robert Tighe appointed as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn, M.D., Ph.D. appointed as Senior Vice President of Clinical Development  Appointments support Ottimo Pharma as it rapidly advances the clinical development of lead candidate, Jankistomig, its first-in-class dual pathway, biparatopic IgG1 therapy  IND clearance for Jankistomig is on track for […]

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair [28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, […]